

1. AMENDMENTS TO THE CLAIMS (LISTING OF CLAIMS):

This listing of claims will replace all prior versions and listings of claims in the application.

1-29. (Cancelled)

30. (New) A method of treating ulcerative colitis, comprising administering an effective amount of a compound of the formula AcPhe[Orn-Pro-D-Cyclohexylalanine-Trp-Arg] to a subject in need thereof.

31. (New) A method of relieving or ameliorating the effects of ulcerative colitis, comprising administering an effective amount of a compound of the formula AcPhe[Orn-Pro-D-Cyclohexylalanine-Trp-Arg] to a subject in need thereof.

32. (New) The method of claim 30 or claim 31, wherein said compound has potent antagonist activity at sub-micromolar concentrations.

33. (New) The method of claim 30 or claim 31, wherein said compound has a receptor affinity $IC_{50} < 25 \mu M$, and an antagonist potency $IC_{50} < 1 \mu M$.

34. (New) The method of claim 30 or claim 31, wherein said subject is human.

35. (New) The method of claim 30 or claim 31, wherein said compound is administered to said subject in conjunction with one or more other agents for the treatment of ulcerative colitis.
36. (New) The method of claim 35, wherein said one or more other agents comprise an inhibitor of TNF- α or C3a.
37. (New) The method of claim 36, wherein said inhibitor of TNF- α is infliximab.
38. (New) The method of claim 36, wherein said inhibitor of C3a is compound SB 290157, which has the formula (Ph₂CHCH₂OCH₂CO-Arg-OH).